RAPT Therapeutics Inc (NASDAQ:RAPT) shares, rose in value on Friday, March 28, with the stock price down by -13.78% to the previous day’s close as strong demand from buyers drove the stock to $1.22.
Actively observing the price movement in the last trading, the stock closed the session at $1.41, falling within a range of $1.185 and $1.405. The value of beta (5-year monthly) was -0.308. Referring to stock’s 52-week performance, its high was $9.65, and the low was $0.79. On the whole, RAPT has fluctuated by 11.93% over the past month.
With the market capitalization of RAPT Therapeutics Inc currently standing at about $161.05 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-05.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RAPT’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of RAPT currently trading nearly 0.23% and 2.31% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 48.47, while the 7-day volatility ratio is showing 12.48% which for the 30-day chart, stands at 9.88%. Furthermore, RAPT Therapeutics Inc (RAPT)’s beta value is -0.36, and its average true range (ATR) is 0.12.
A comparison of RAPT Therapeutics Inc (RAPT) with its peers suggests the former has fared considerably weaker in the market. RAPT showed an intraday change of -13.78% in last session, and over the past year, it shrunk by -85.48%%.
Data on historical trading for RAPT Therapeutics Inc (NASDAQ:RAPT) indicates that the trading volumes over the past 10 days have averaged 1.37 and over the past 3 months, they’ve averaged 949.07K. According to company’s latest data on outstanding shares, there are 132.01 million shares outstanding.
Nearly 47.81% of RAPT Therapeutics Inc’s shares belong to company insiders and institutional investors own 45.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.67 million shares as on 2025-03-14, resulting in a short ratio of 5.84. According to the data, the short interest in RAPT Therapeutics Inc (RAPT) stood at 217.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 2.81 million. The stock has fallen by -22.78% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RAPT stock heading into the next quarter.
